Related content

Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women

By Ringe J. D.   Christodoulakos G. E.   Mellström D.   Petto H.   Nickelsen T.   Marín F.   Pavo I.  

Current Medical Research and Opinion, Vol. 23, Iss. 11, 2007-11 ,pp. : 2677-2687

Informa Healthcare

Access to resources Recommend Favorite

A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis

By Gold Deborah T.   Martin Bradley C.   Frytak Jennifer R.   Amonkar Mayur M.   Cosman Felicia  

Current Medical Research and Opinion, Vol. 23, Iss. 3, 2007-03 ,pp. : 585-594

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial

By Ström O.   Borgström F.   Sen S.   Boonen S.   Haentjens P.   Johnell O.   Kanis J.  

Osteoporosis International, Vol. 18, Iss. 8, 2007-08 ,pp. : 1047-1061

Springer Publishing Company

Access to resources Recommend Favorite

Comparison of Bone and Total Alkaline Phosphatase and Bone Mineral Density in Postmenopausal Osteoporotic Women Treated with Alendronate

By Watts N. B.   Jenkins D. K.   Visor J. M.   Casal D. C.   Geusens P.  

Osteoporosis International, Vol. 12, Iss. 4, 2001-05 ,pp. : 279-288

Springer Publishing Company

Access to resources Recommend Favorite

Alendronate Reduces the Excretion of Risk Factors for Calcium Phosphate Stone Formation in Postmenopausal Women with Osteoporosis

By  

Urologia Internationalis, Vol. 83, Iss. 2, 2009-09 ,pp. : 226-229

Karger

Access to resources Recommend Favorite